Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Bruker; Hologic, Immucor; Cancer Genetics; New England Biolabs; Genewiz; Genedata

NEW YORK (GenomeWeb News) – Investment bank Jefferies this week upgraded Bruker's stock to Buy from Hold and upped its price target on the stock from $20 to $25. "We have increased confidence in [Bruker's] intermediate-term profit and cash flow trajectories, and see more than [an] adequate degree of conservatism in its formal 2013 outlook," Jefferies analyst Jon Wood wrote in a note published Thursday.


Hologic has completed the sale of its Lifecodes business to Immucor. LifeCodes specializes in pre-transplant human leukocyte antigen typing and screening as well as post-transplant patient monitoring. It became part of Hologic through the acquisition of Gen-Probe last summer. Hologic said in January that it would sell the business to Immucor for up to $95 million — $85 million in cash, and potentially up to an additional $10 million in earn-out payments.


Cancer Genetics this week revised its planned initial public offering again, saying it expects net proceeds of approximately $3.7 million, or $4.6 million if the underwriters on the offering, Aegis Capital and Feltl & Co., exercise their over-allotment options in full.

The company now said it plans to offer 600,000 shares of its stock at a price of between $10 and $12 per share. The net proceed figures are based on a mid-point share price of $11.

The Rutherford, NJ.-based company has revised its planned IPO several times since it initially filed its Form S-1 in December 2011. Earlier this month, it said that expected net proceeds of about $14.3 million, or $16.8 million if Aegis Capital and Feltl & Co., exercise their overallotment in full.


New England Biolabs said this week that it has opened a subsidiary in Singapore. The Ipswich, Mass.-based firm said that the subsidiary is its seventh.


Genewiz, a South Plainfield, NJ-based CRO specializing in genomics services, said this week that it has received accreditation from the College of American Pathologists.


Genedata announced this week its participation in the EpiFemCare research project, an EU-funded effort focused on improving diagnosis and treatment of breast and ovarian cancer. Genedata said that it will "manage, process, and analyze terabytes of epigenetic and clinical data from next-generation sequencing, microarray and qPCR experiments to help identify, confirm and clinically validate biomarkers."


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.